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Abstract
Background: Preliminary studies suggest that physical exercise interventions can improve physical fitness, fatigue
and quality of life in cancer patients after completion of chemotherapy. Additional research is needed to rigorously
test the effects of exercise programmes among cancer patients and to determine optimal training intensity
accordingly. The present paper presents the design of a randomized controlled trial evaluating the effectiveness
and cost-effectiveness of a high intensity exercise programme compared to a low-to-moderate intensity exercise
programme and a waiting list control group on physical fitness and fatigue as primary outcomes.
Methods: After baseline measurements, cancer patients who completed chemotherapy are randomly assigned to
either a 12-week high intensity exercise programme or a low-to-moderate intensity exercise programme. Next,
patients from both groups are randomly assigned to immediate training or a waiting list (i.e. waiting list control
group). After 12 weeks, patients of the waiting list control group start with the exercise programme they have
been allocated to.
Both interventions consist of equal bouts of resistance and endurance interval exercises with the same frequency
and duration, but differ in training intensity. Additionally, patients of both exercise programmes are counselled to
improve compliance and achieve and maintain an active lifestyle, tailored to their individual preferences and
capabilities.
Measurements will be performed at baseline (t = 0), 12 weeks after randomization (t = 1), and 64 weeks after ran-
domization (t = 2). The primary outcome measures are cardiorespiratory fitness and muscle strength assessed by
means of objective performance indicators, and self-reported fatigue. Secondary outcome measures include health-
related quality of life, self-reported physical activity, daily functioning, body composition, mood and sleep distur-
bances, and return to work. In addition, compliance and satisfaction with the interventions will be evaluated.
Potential moderation by pre- and post-illness lifestyle, health and exercise-related attitudes, beliefs and motivation
will also be assessed. Finally, the cost-effectiveness of both exercise interventions will be evaluated.
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Discussion: This randomized controlled trial will be a rigorous test of effects of exercise programmes for cancer
patients after chemotherapy, aiming to contribute to evidence-based practice in cancer rehabilitation programmes.
Trial registration: This study is registered at the Netherlands Trial Register (NTR2153)
Background
Cancer treatment has made substantial progress in the
last decades. Survival rates after cancer treatment have
improved up to 56% in male and 62% in female patients
[1]. This is a major achievement; it is, however, impor-
tant to acknowledge that cancer and cancer treatment
are associated with long-term physical and psychosocial
side effects. These sequelae include decreased muscle
strength, reduced cardiorespiratory fitness, reduced lean
body mass, bone loss, severe feelings of fatigue [2,3],
depression, emotional distress, anxiety and decreased
self-esteem [4]. Fatigue is one of the most common side
effects of cancer treatment, affecting approximately 70%
of the cancer population receiving radiation therapy and
chemotherapy [5,6]. Even years after treatment, feelings
of fatigue persist in 30% of cancer patients [7]. This has
great impact on the patient’s quality of life [5,8].
Cancer rehabilitation programmes have become a
great matter of interest as component of cancer patient
care to reduce the side effects of cancer treatment and
to enhance a patient’s quality of life. In the Netherlands,
two cancer rehabilitation programmes have been evalu-
ated in previous years. The first programme was based
on a biopsychosocial approach, combining physical exer-
cise with psychosocial activities in a group format. Exer-
cise started with low-to-moderate intensities, and
workload increased gradually after four weeks training
[9]. The second cancer rehabilitation programme
focused on high intensity resistance and endurance exer-
cise [10]. Both rehabilitation programmes were well tol-
erated by most patients and improvements in physical
fitness and health-related quality of life were reported,
directly after completion of the programmes [10,11] and
after respectively 9 [12] and 12 months [13] follow-up.
Systematic reviews of the literature [14-17] underline
the positive physical and psychosocial benefits from
exercise programmes accordingly. Evidence suggests
that exercise may result in improved physical fitness,
reduced levels of fatigue and enhanced health-related
quality of life. However, the results must be interpreted
with caution [14,18]. Overall, the methodological quality
of many of the studies reviewed was moderate and
opportunities to improve the scientific methodology
were evident. Authors of the reviews suggested includ-
ing larger sample sizes, using appropriate control
groups, and using a comparable set of valid and reliable
outcome measures in future randomized controlled
trials (RCTs). Moreover, certain aspects of the examined
exercise programmes were less than optimal: most exer-
cise programmes were relatively short in duration (less
than 12 weeks), the programmes did not stimulate the
patients to stay physically active after the programme,
and studies frequently included aerobic exercises such
as walking and cycling, but no resistance exercises.
Accumulating evidence suggests that resistance exer-
cises may have great potential as well [15,19]. A recent
systematic review of twenty-four studies evaluating resis-
tance exercise in cancer patients post-treatment [20]
reported beneficial effects on cardiorespiratory fitness
and muscle strength. Furthermore, the studies included
in the review did not report adverse effects, indicating
that resistance exercise was well-tolerated. Courneya et
al. [21] compared aerobic exercise with resistance exer-
cise in breast cancer patients. While aerobic exercises
showed significant improvements in self-esteem, pre-
served aerobic fitness, and maintained body fat levels,
resistance exercises significantly improved self-esteem,
muscle strength, and lean body mass. A recent roundta-
ble, organised by the American College of Sports and
Medicine (ACSM), came to consensus that both aerobic
and resistance exercise are recommended to be pre-
scribed in cancer patients [22].
Current ACSM exercise recommendations for cancer
patients include moderate intensity exercises with aero-
bic exercises at 40% to 60% of heart rate reserve (HRR)
three to five times per week for 20 to 60 minutes and
resistance exercises at 40% to 60% of one-repetition
maximum (1-RM) two or three times per week with one
to three sets of 8 to 12 repetitions per exercise [23].
However, the ACSM acknowledges the remaining gap in
existing knowledge on the optimal mode, frequency,
duration and intensity of exercise [22]. High intensity
exercise has shown to improve physical fitness and
enhance health-related quality of life in cancer patients
who competed chemotherapy [10]. Also in patients with
heart failure, high intensity exercise was feasible and
resulted in greater improvements in physical fitness as
compared to lower intensity exercise [24].
High quality scientific research is needed to firmly
establish the range and magnitude of positive effects of
exercise programmes among cancer patients and to
determine optimal exercise intensities in this population.
This paper presents the design of a randomized con-
trolled multi-centre trial to evaluate the effectiveness
and cost-effectiveness of a high intensity exercise pro-
gramme compared to a low-to-moderate intensity
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exercise programme and a waiting-list control group on
physical fitness (cardiorespiratory fitness and muscle
strength), and fatigue in cancer patients who completed
chemotherapy. We hypothesize that patients in both
exercise programmes will achieve more muscle strength,
greater gains in cardiorespiratory fitness and will report
lower levels of fatigue compared to the patients who are
allocated to the waiting list control group. Furthermore,
we hypothesize these improvements to be greater in
patients who completed the high intensity exercise pro-
gramme compared to patients who completed the low-
to-moderate intensity exercise programme, both on the
short and longer (at one year follow-up) term. Addition-
ally, we compare the cost-effectiveness of the high
intensity exercise programme with the low-to-moderate
intensity exercise programme.
Methods
The Resistance and Endurance exercise After Che-
moTherapy (REACT) study is one of four RCTs included
in the Alpe d’HuZes Cancer Rehabilitation (A-CaRe) pro-
gram [25]. All four studies in this programme have been
designed to evaluate the effectiveness and cost-effective-
ness of exercise-based rehabilitation programmes in dif-
ferent cancer patient groups. Figure 1 shows the design
of the REACT study and the flow of eligible patients
through the trial. The Medical Ethics Committee of the
Máxima Medical Center approved the study.
Study sample
Patients with histological confirmed primary breast,
colon or ovarian cancer, or lymphomas with no indica-
tion of recurrent or progressive disease, who completed
(adjuvant) chemotherapy with curative intention, and
aged between 18 and 70 years are eligible for this study.
Patients who are not able to perform basic activities of
daily living such as walking or biking, who show cogni-
tive disorders or severe emotional instability, who are
suffering from other disabling comorbidity that might
hamper physical exercise (e.g. heart failure, chronic
obstructive pulmonary disease (COPD), orthopaedic
conditions and neurological disorders), and patients who
are unable to understand and read the Dutch language
are excluded from the study.
Recruitment and randomization
The patients are recruited from three hospitals in the
southern part of the Netherlands: Máxima Medical Cen-
ter (Veldhoven/Eindhoven), Catharina Hospital (Eindho-
ven), and Elkerliek Hospital (Helmond). Expectations
are that more hospitals in the southern part of the
Netherlands will be invited to collaborate.
In consultation with the treating medical oncologist,
the oncology nurse determines if patients in their
clinical setting are eligible for the study. All potentially
eligible patients receive written information to take
home. Next, patients are contacted by telephone and
invited to query any question about the study. Patients
who are willing to participate are asked to provide writ-
ten informed consent.
After completing all baseline measurements, patients
are stratified by tumour type and hospital and randomly
assigned to one of the following groups: 1) high inten-
sity exercise programme or 2) low-to-moderate intensity
exercise programme. Next, patients from both groups
are randomly assigned to immediate training or waiting
list (i.e. waiting list control group). After 12 weeks,
patients of the waiting list control group start with the
exercise programme they have been allocated to. The
research assistant uses statistical software for randomi-
zation of the sample and informs patients about the
results. Allocation sequence is concealed from the medi-
cal team. Study outcomes are assessed by a blinded pro-
fessional and patients are instructed not to reveal their
treatment allocation.
Patients who choose not to participate in the REACT
study are asked to complete a one time survey. This
questionnaire includes relevant characteristics, the rea-
son for not participating and questions on the current
attitudes towards and beliefs about exercise.
Intervention
This study includes three arms: a high intensity exercise
programme, a low-to-moderate intensity exercise pro-
gramme, and a waiting list control group. Both interven-
tions consist of equal bouts of resistance and endurance
interval exercises with similar frequency and duration;
the exercise programmes differ in training intensity only.
All patients train in groups of a maximum of eight
persons, on specific resistance training equipment and
ergometers (e.g. bicycle, treadmill), twice a week for 12
weeks under supervision of a physiotherapist. Addition-
ally, a physical active lifestyle is stimulated in both inter-
ventions groups equally, using behavioural motivational
techniques (see below; Behavioural motivational coun-
selling programme). The safety of both exercise pro-
grammes is guaranteed by a comprehensive intake
procedure performed by a sports physician or rehabilita-
tion specialist. Medical history together with possible
physical limitations is reported, and if necessary, adapta-
tions in training methods or specific advice to patient
and physiotherapists are provided.
Intervention A; High intensity exercise programme
The high intensity resistance exercise session consists of
six exercises targeting the large muscle groups as fol-
lows: 1) vertical row (focusing on m. longissimus, m.
biceps brachii, m. rhomboideus); 2) leg press (m. quadri-
ceps, m. glutei, m. gastrocnemius); 3) bench press (m.
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pectoralis major, m. triceps); 4) pull over (m. pectoralis,
m. triceps brachii, m. deltoideus, m. trapezius); 5)
abdominal crunch (m. rectus abdominis); 6) lunge (m.
quadriceps, m. glutei, hamstring muscles). Resistance
exercises are performed at 70-85% of 1-RM and consist
of two sets of 10 repetitions. Every four weeks (week 5
and 9) the training progress is evaluated by means of an
indirect 1-RM test, and the resistance is adjusted
accordingly. The 1-RM is the greatest resistance that
can be moved through the full range of motion in a
controlled manner with good posture, and is considered
to be the standard for dynamic strength assessment
[26]. To minimize the risk of injury we apply an indirect
1-RM measurement. Following a warm-up, the phy-
siotherapist estimates a workload at which the patient is
expected to perform approximately four to eight repeti-
tions, taking into consideration sex, height and age. In
case that the physiotherapist’s judgement regarding this
workload proves to be incorrect, another assessment
will be carried out a little later.
The first four weeks, the high intensity endurance
interval exercises consist of two times eight minutes
cycling, with alternating workloads: 30 seconds at a
workload of 65% of the maximal workload assessed by
the steep ramp test and 60 seconds at 30%. From the
fifth week onwards, the duration of the latter block is
reduced to 30 seconds. Every four weeks, the training
progress is evaluated by means of the steep ramp test,
and the workload is adjusted accordingly. The steep
ramp test is an incremental bicycle ergometer test, in
which the patient is instructed to cycle at a rate between
70 and 80 revolutions per minute (RPM), starting at 25
watt (W), after which the load is increased by 25W
every 10 seconds. The test ends if cycling rate falls
Figure 1 Design and Procedures of the study.
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below 60 RPM. The obtained maximal workload during
the steep ramp test, indicated as maximal short exercise
capacity (MSEC) [27], the time cycled at that load and
heart rate (HR) at the end of the test are recorded. The
steep ramp test has shown to be a reliable (Intraclass
Correlation Coefficient (ICC) = 0.996) and valid (corre-
lation with peakVO2 = 0.85) test to estimate maximal
workload in cancer patients [27].
From the fifth week onwards, an additional endurance
interval session is included in the programme, in
exchange for one block of eight minutes cycling. This
interval session consists of three bouts of five minutes
with one minute of rest in between each bout. During
the five minutes of exercise, patients train on erg-
ometers (e.g. cycle ergometer or treadmill) at a constant
workload in which the training HR is 80% of their HRR
or higher. Training HR is determined by using the Kar-
vonen formula [28], using the maximum heart rate
(peak HR) obtained from baseline measurements and
heart rate at rest (HR rest).
Intervention B; Low-to-moderate intensity exercise
programme
Resistance exercise session of the low-to-moderate
intensity exercise programme consists of the same six
exercises as the high intensity exercise programme, but
with lower intensity. All exercises are performed at 40-
55% of 1-RM, with a frequency of two sets of 10
repetitions.
The low-to-moderate intensity endurance interval
exercises start with two times cycling of eight minutes
as well. The alternating workloads are adjusted in 30
seconds at a workload of 45% of the MSEC assessed by
the steep ramp test and 60 seconds at 30%. From week
five onwards, the duration of the latter block is reduced
to 30 seconds in a similar way.
Every four weeks (week 5 and 9) training progress of
the resistance and endurance interval exercises are eval-
uated and adjusted accordingly.
Comparable to the high intensity programme, from
the fifth week onwards one block of eight minutes
cycling is exchanged by an additional endurance inter-
val session which consists of three bouts of five min-
utes, with one minute of rest in between each bout.
Patients who follow the low-to-moderate exercise pro-
gramme should achieve 40-50% of their HRR during
these three bouts of five minutes of exercise at a con-
stant workload.
Behavioural motivational counselling programme
A behavioural motivation component is included to
improve compliance and stimulate physical activity out-
side the exercise programme. Patients are encouraged to
be moderately physically active for at least 30 minutes,
three times per week in addition to the supervised exer-
cise programme. After completion of the 12-week
exercise intervention, patients are encouraged to main-
tain an active lifestyle with the aim to be moderately
physically active for at least 30 minutes three times per
week as well as to continue with physical exercises at a
higher intensity level for at least 20 minutes two times
per week [23]. Specific programme elements include the
provision of general and motivational information about
physical activity, both verbally and via folders, and dis-
cussing individual barriers and facilitators. Behavioural
motivational counselling is offered by the physiothera-
pist in close collaboration with the sports physician or
rehabilitation specialist.
Waiting list control group
The control arm of this trial consists of a waiting list in
order to control for spontaneous recovery over time.
Patients from the waiting list control group start either
with the high intensity exercise programme or the low-
to-moderate intensity exercise programme after 12
weeks.
Study Outcomes
All studies within A-CaRe Clinical Research use similar
methodologies and a comparable set of outcome mea-
sures [25]. Within the REACT study, primary and sec-
ondary outcome measures are assessed at baseline (t =
0) at the time of inclusion in the trial (4-6 weeks after
ending chemotherapy), 12 weeks after randomization (t
= 1), and 64 weeks after randomization (t = 2). For
logistic reasons, all physical tests are conduced centrally
at Máxima Medical Center in Eindhoven. All profes-
sionals follow detailed and standardized test protocols.
The questionnaires can be completed at home or via
internet.
Primary outcome measures
Cardiorespiratory fitness
Cardiorespiratory fitness is measured during a maximal
exercise test on an electronically braked cycle ergometer
according to a ramp protocol [29], in which the resis-
tance gradually increases every six seconds aiming to
achieve the maximum within 8 to 12 minutes. All
patients are instructed to cycle with a pedal frequency
between 70 and 80 RPM, and are encouraged to con-
tinue exercising until exhaustion, or inability to maintain
the pedal frequency of 70 RPM. Expired gases are col-
lected and analyzed breath by breath for O2, CO2, and
volume. The average values of the last 30 seconds of
exercise are used as measures for peak oxygen uptake
(peakVO2, in l/min), peak power output (peakW, in
watt), and peak HR. Ventilatory threshold is determined
by the oxygen equivalent method [30], using the average
value obtained by two independent observers. HR and
respiratory exchange ratio (RER) are used as objective
criteria for peak exercise.
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Muscle strength
Upper extremity muscle strength is assessed by using a
JAMAR grip strength dynamometer. Each patient is
asked to grip first right-handed then left-handed three
consecutive times. The maximum score in terms of kilo-
grams is recorded for each side. Handgrip dynamometry
can be used to characterize general upper limb muscle
strength dynamometer [31-33]. Handgrip strength can
increase after general resistance training of the upper
extremities, consisting of exercises that did not specifi-
cally involve hand grip strength [34].
Lower extremity muscle strength is assessed by the 30
seconds chair stand test [35]. The patient is asked to
stand upright from a chair with their arms folded across
the chest, then to sit down again and then repeat the
action at his or her fastest pace over a 30 seconds per-
iod. The final test score is the number of times that the
subject rises to a full stand [35,36]. The 30 seconds
chair stand test is a valid and reliable measure of proxi-
mal lower limb strength in older adults [37].
Fatigue
Two self-report questionnaires are used to assess fati-
gue: the Multidimensional Fatigue Inventory (MFI)
[38,39] and the Fatigue Quality List (FQL) [40].
The MFI is a questionnaire consisting of 20 state-
ments for which the person has to indicate on a 0-5
scale to what extent the particular statement applies to
him or her. This self-report instrument consists of five
subscales based on different dimensions: general fatigue,
physical fatigue, reduced physical activity, reduced moti-
vation and mental fatigue. The MFI subscales have
exhibited adequate reliability for purposes of group
comparisons and has good known group validity [38].
The patients’ perception and appraisal of experienced
fatigue is assessed with the FQL. The FQL consists of
25 adjectives describing the fatigue experience, orga-
nized into four subscales: frustrating, exhausting, plea-
sant, and frightening.
Secondary outcome measures
The REACT study assesses the following secondary out-
come measures: health-related quality of life, body com-
position, bone mineral density, neuropathy, objective
and self-reported daily physical activity level, mood and
sleep disturbances, functioning in daily life, return to
work, cost from a social perspective, adverse events,
compliance and satisfaction with the intervention. In
addition, clinical data, disease status and treatment,
sociodemographic characteristics, moderating variables
of the exercise programme and adverse events will be
recorded. A complete overview of primary and second-
ary outcome measures is provided in Table 1. A small
selection of these secondary measures is described in
detail below. A detailed description of the secondary
outcome measures, common to all four trials, are
described in an overall design paper [25].
Sociodemographic and clinical data
Sociodemographic data such as age, level of education,
marital status, living situation, medication use (including
alternative medications or therapies) and lifestyle vari-
ables (e.g. smoking) are obtained by questionnaire.
Clinical information, including date of diagnosis, stage
and subtype of disease, and treatment history is
obtained from medical records. During the follow-up
period, data on disease status (response to treatment,
progression or relapse) and data on any additional treat-
ment are collected.
Moderating variables
At baseline, a series of questions is used to assess a
number of potential moderating variables, including pre-
illness lifestyle (frequency, nature and intensity of daily
physical activity and exercise behaviour, or avoidance
thereof), current attitudes towards and beliefs about
exercise and daily physical activity in general, and about
exercising after chemotherapy. These questions are
adapted from measures developed by Courneya and col-
leagues [41,42] for use in evaluating exercise in cancer
survivors, and are based on established health behaviour
theories, in particular the Theory of Planned Behaviour
[42].
Costs from a societal perspective
Besides the costs of the exercise programmes, data on
health care costs, patient and family costs, and costs of
production losses are collected using cost diaries admi-
nistered on a 3-monthly basis during the entire follow-
up period. Health care costs include the costs of oncolo-
gical care, general practice care and physiotherapy, addi-
tional visits to other health care providers, prescription
of medication, professional home care and hospitaliza-
tion. Patient and family costs include out-of-the-pocket
expenses such as travel expenses, over-the-counter med-
ication, and costs for paid and unpaid help. Costs
related to production losses include work absenteeism
for patients with paid jobs, and days of inactivity for
patients without a paid job.
Power calculations
Power calculation is based on the effects on physical fit-
ness and fatigue found in the study by De Backer et al.
[13] examining the long-term effects of a high intensity
resistance and endurance exercise programme after can-
cer treatment compared with natural recovery.
With a sample size of 80 we are able to detect a dif-
ference in fatigue of 9 points (EORTC QLQ-C30), with
a standard deviation (SD) of 20, a power of 0.80 and
two sided alpha of 0.05. Additional power calculations
(a power of 0.80 and alpha of 0.05) for muscle strength
(vertical row) and cardiorespiratory fitness (peakVO2)
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showed that this sample size enables us to detect a dif-
ference in vertical row of 0.09 1-RM/kg (SD 0.20) and a
difference in peakVO2 of 3 ml/min/kg (SD 7). Both sup-
plementary calculations are based on differences in
results reported by the same research group [13].
To compensate for dropouts and taking into account
the multi-level design we aim to enrol 40% more
patients, therefore in total 120 subjects per group. Since
we expect smaller differences between the high intensity
exercise group and the low-to-moderate intensity exer-
cise group, we have decided to enlarge these two groups
to 140 subjects per group. The waiting list control
group will consist of 120 patients.
Statistical analysis
Baseline characteristics of the two intervention groups
and control group with regard to the most important
prognostic indicators and main outcome measures will be
compared to assess the adequacy of the randomization. If
necessary, adjustments will be made for baseline charac-
teristics. In a similar way, we will assess differences
between responders and non-responders with regard to
the most important prognostic indicators in order to
describe the generalizability of the results.
Data are analyzed according to the intention-to-treat
principle. In addition, per protocol analysis will be per-
formed, in which only patients will be included who
attained 75% of all exercise sessions.
Scores on the self-report measures of fatigue, mood
state and health-related quality of life will be calculated
according to published scoring algorithms. Multilevel
longitudinal regression analysis will be conducted to
assess changes in each outcome measure. The follow-up
measurements will be defined as dependent variable and
the following levels are used, 1) time of follow-up mea-
surement (values corresponding with performance at t1
and t2); 2) training centre 3) individual. Regression coef-
ficients will indicate differences between interventions
Table 1 Overview Primary and Secondary outcome measures
Outcome measures Instrument
A. Primary outcome measures
Cardiorespiratory fitness Maximum exercise test (peakVO2 )
Muscular strength 30 s sit-to-stand test, maximal handgrip strength
Fatigue Multidimensional Fatigue Inventory (MFI) [38] and the Fatigue Quality List (FQL) [40] questionnaires
B. Secondary outcome
measures
Sociodemographic data Age, education, marital status, living situation, comorbidities and life style variables (e.g. smoking)
Clinical data
Medical history Date of diagnosis, subtype of disease, stage of disease, history of therapy
Disease status and treatment Response to treatment, progression or relapse of disease and data on any additional treatment will be recorded
from medical records
Adverse events Medical records, reports of the sports physician and physical therapist
Physical tests
Physical examination Height, weight, waist and hip circumferences, four skinfolds (biceps, triceps, suprailiacal and subscapular)
Body composition and bone
mineral density
Dual Energy X-ray (DXA) scan
Questionnaires
Health-related quality of life EORTC Quality of Life Questionnaire C30 (EORTC QLQ-C30) [43], EuroQol (EQ5D) [44], EORTC Chemotherapy-
induced peripheral neuropathy module (QLQ-CIPN20) [45]
Physical activity Physical Activity Scale for the Elderly (PASE) [46], Recordings of the Actitrainer accelerometer (Actigraph, Fort
Walton Beach Florida, USA)
Mood disturbance Hospital Anxiety and Depression Scale (HADS) [47,48]
Functioning in daily life Impact on Participation and Autonomy (IPA) [49]
Quality of Sleep Pittsburgh Sleep Quality Index (PSQI) [50]
Return to work Return to work questionnaire
Moderating variables Questionnaire about pre-illness lifestyle, current attitudes toward and beliefs about exercise in general
Satisfaction with the intervention Satisfaction questionnaire
Cost questionnaires Cost dairies
Compliance with the exercise
program
Self-report and objective measures (e.g. attendance, exercise logs, target intensity)
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and control group. Regression models will be adjusted
for gender, baseline values, and compliance. Missing
values will be avoided as much as possible by asking
participants to comply with the post-treatment and fol-
low-up measurement even after they drop out from the
exercise programme. In the event of missing values, the
mixed linear regression modelling will account for them.
Cost-effectiveness analysis
The economic evaluation includes cost-effectiveness and
cost-utility analysis from a societal perspective, and will
be performed according to the intention-to-treat princi-
ple. Detailed descriptions of the economic evaluation are
described in the overall design paper [25].
Discussion
This project aims to contribute to evidence-based prac-
tice in cancer rehabilitation programmes. We evaluate
the effectiveness of exercise in cancer patients with
respect to improving physical fitness and reducing fati-
gue. Preliminary results in the literature are promising.
Yet, the suggested positive physical and psychosocial
outcomes of exercise programmes among cancer
patients need to be confirmed in large, well-designed
trials.
The REACT study evaluates the effectiveness and
cost-effectiveness of a high intensity exercise programme
compared to a low-to-moderate exercise programme,
and a waiting list control group. In this way, we will
obtain more insight in outcomes of different training
intensities. Furthermore, if exercise appears effective, it
becomes vital to evaluate cost-effectiveness and cost sav-
ings for health care utilization since exercise-based reha-
bilitation programmes do not yet form part of standard
cancer care for cancer patients and survivors.
The following suggestions made by the systematic
reviews have been incorporated to strengthen our meth-
odology; applying a larger sample and long-term follow-
up measurements, incorporating randomization of
patients to appropriate comparison groups, including
concealed allocation and blinded outcome assessment,
and using intention-to-treat and per protocol analyses.
Most studies so far have focused on breast cancer
patients [16-18]. The inclusion criteria of the present
study include as many as four cancer diagnoses (primary
breast, colon or ovarian cancer, or lymphomas) allowing
to explore whether patients with different cancer types
respond differently to exercise. Furthermore, detailed
evaluation of current attitudes towards and beliefs about
exercise of both responders and non-responders are
obtained. This provides insight concerning the generaliz-
ability of the results from this RCT.
Limitations of the study should be noted as well.
Instead of a ‘true’ non-exercising control group, the
present study includes a waiting list control group. Due
to the growing availability of cancer rehabilitation
groups in daily clinical practices in the study region,
patients’ expectations may not be met, and higher drop-
out rates could occur with a non-exercising control
group. However, the use of a waiting list control group
does not allow long-term follow-up measurements,
because after 12 weeks these patients start the exercise
programme they have been allocated to.
The prescribed design of resistance and endurance
interval exercises in the present study is originally based
on the intervention assessed by De Backer et al. (2007)
[9]. To improve the earlier exercise programme and to
be more closely aligned to the ACSM guidelines [23],
we added an additional endurance interval session with
a constant workload. Hence, the resulting combination
of exercises is in our opinion state-of-the-art, included
in a firm study design.
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